Revelation Biosciences Inc. has announced positive top-line results from its Phase 1b PRIME clinical study involving its investigational product, Gemini, in patients with stage 3 and 4 chronic kidney disease (CKD). The study successfully met its primary endpoint, demonstrating the safety and tolerability of escalating doses of Gemini. Additionally, Gemini significantly reduced inflammatory activity and restored normal cellular responses, as indicated by measurements taken from peripheral blood mononuclear cells at various intervals post-dose. The results suggest Gemini's potential in rebalancing inflammation, which could benefit both acute and chronic inflammatory conditions. These findings were presented in a webcast/conference call held on September 10, 2025. Revelation Biosciences plans to publish these results and continue further data analysis.